55275-61-1

Basic information

• Product Name: alpha-(aminomethyl)-4-methoxybenzyl alcohol
• Synonyms: alpha-(aminomethyl)-4-methoxybenzyl alcohol;α-(AMinoMethyl)-p-anisyl Alcohol;BENZENEMETHANOL, α-(AMINOMETHYL)-4-METHOXY-;Benzenemethanol, a-(aminomethyl)-4-methoxy-
• CAS NO: 55275-61-1
• Molecular Formula: C₉H₁₃NO₂
• Molecular Weight: 167.20502
• EINECS: 259-561-7
• Mol File: 55275-61-1.mol
• Article Data: 23

Chemical Properties

• Melting Point: 70℃
• Boiling Point: 325.4°C at 760 mmHg
• Flash Point: 150.6°C
• Appearance: /
• Density: 1.128±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 9.43E-05mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: alpha-(aminomethyl)-4-methoxybenzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: alpha-(aminomethyl)-4-methoxybenzyl alcohol(55275-61-1)
• EPA Substance Registry System: alpha-(aminomethyl)-4-methoxybenzyl alcohol(55275-61-1)

Safety Data

• Hazardous Substances Data: 55275-61-1(Hazardous Substances Data)

Usage

Description

alpha-(aminomethyl)-4-methoxybenzyl alcohol is an organic compound with the molecular formula C8H11NO2. It is a derivative of benzyl alcohol, featuring an aminomethyl group and a methoxy group attached to the benzene ring. alpha-(aminomethyl)-4-methoxybenzyl alcohol is known for its potential applications in the pharmaceutical industry due to its unique structural properties.

Uses

Used in Pharmaceutical Synthesis:
alpha-(aminomethyl)-4-methoxybenzyl alcohol is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of derivatives with potential therapeutic applications.
Used in the Preparation of Marine Alkaloid Derivatives:
In the field of marine pharmacology, alpha-(aminomethyl)-4-methoxybenzyl alcohol is used as a starting material for the preparation of derivatives of the marine alkaloid tsitsikammamine A. These derivatives have demonstrated inhibitory activity, making them valuable for further research and potential development as therapeutic agents.
Used in the Synthesis of Aegeline (A325500):
alpha-(aminomethyl)-4-methoxybenzyl alcohol also serves as an intermediate in the synthesis of Aegeline, a compound with the CAS number A325500. Aegeline is a natural product with potential pharmacological properties, and the development of efficient synthetic routes to this compound is of interest to the pharmaceutical industry.

InChI:InChI=1/C9H13NO2/c1-12-8-4-2-7(3-5-8)9(11)6-10/h2-5,9,11H,6,10H2,1H3

Upstream product

• 33646-40-1 4-methoxymandelonitrile 
• 1823-76-3 p-methoxy-isonitrosoacetophenone 
• 14271-83-1 4-methoxybenzoyl cyanide 
• 75-52-5 nitromethane 
• 123-11-5 4-methoxy-benzaldehyde 
• 99843-19-3 acetoxy-(4-methoxy-phenyl)-acetonitrile 
• 66985-48-6 2-(4-methoxyphenyl)-2-(trimethylsilyloxy)acetonitrile 
• 64-17-5 ethanol 
• 38316-05-1 1-(4-methoxy-phenyl)-2-nitro-ethanol 
• 64-19-7 acetic acid 
• 7732-18-5 water 
• 3883-94-1 2-amino-4'-methoxyacetophenone hydrochloride 
• 291301-32-1 C₁₉H₁₇N₃O₂ 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 15298-28-9 N-(2-hydroxy-2-(4-methoxyphenyl)ethyl)benzamide 
• 6821-73-4 3-phenyl-propionic acid-(β-hydroxy-4-methoxy-phenethylamide) 
• 33864-03-8 O-methylhalfordinol 
• 35988-40-0 5-(4-methoxy-phenyl)-oxazolidine-2-thione 
• 3876-13-9 5-(4-methoxy-phenyl)-4,5-dihydro-oxazol-2-ylamine 
• 81316-55-4 2-<(2-chloro-3,4-dimethoxyphenyl)methyl>-5-(4-methoxyphenyl)-2-oxazoline 
• 104421-98-9 N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(2-bromo-3,4-dimethoxyphenyl)acetamide 
• 104421-99-0 N-<2-(4-methoxyphenyl)-2-hydroxyethyl>-2-(3,4-dimethoxy-2-fluorophenyl)acetamide 
• 104422-01-7 N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(3,4-dimethoxyphenyl)acetamide 
• 62717-74-2 N-[2-(3,4-dimethoxyphenyl)-ethyl]-2-hydroxy-2-(4-methoxyphenyl)ethylamine 
• 104421-93-4 7,8-Dimethoxy-1-(4-methoxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 72912-25-5 6-Fluoro-7,8-dimethoxy-1-(4-methoxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 95413-95-9 N-<2-hydroxy-2-(4-methoxyphenyl)>-2-(3,4-dimethoxy-2-fluorophenyl)ethylamine 
• 104421-94-5 3-Allyl-7,8-dimethoxy-1-(4-methoxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 

Relevant articles and documents

A N - [2 - hydroxy -2 - (4 - methoxyphenyl) ethyl] cinnamic amide synthesis method (by machine translation)

The present invention provides a N - [2 - hydroxy - 2 - (4 - methoxyphenyl) ethyl] cinnamic amide synthesis method, the method is to methoxy acetophenone as the starting material, through chlorination reaction, azide reaction, condensation reaction by the reaction of reduction. The invention available reaction raw materials, the reaction process is simple in operation, reaction low equipment requirements, relatively mild reaction conditions, yield, the content is high, the final resulting N - [2 - hydroxy - 2 - (4 - methoxyphenyl) ethyl] cinnamide of liquid phase HPLC purity is greater than 99%. (by machine translation)

Chiral-Organotin-Catalyzed Kinetic Resolution of Vicinal Amino Alcohols

A highly efficient kinetic resolution of racemic amino alcohols has been achieved for the first time with a chiral tin catalyst. A chiral organotin compound with 3,4,5-trifluorophenyl groups at the 3,3′-positions of the binaphthyl framework enabled this transformation with excellent yield and high enantioselectivity. The process tolerates aryl- and alkyl-substituted amino alcohols and a variety of other substrates, affording the corresponding products in high enantioselectivity and with s factors up to >500.

Synthesis, molecular modelling and CYP24A1 inhibitory activity of novel of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides

CYP24A1 (25-hydroxyvitamin D-24-hydroxylase) is a useful enzyme target for a range of medical conditions including cancer, cardiovascular and autoimmune disease, which show elevated CYP24A1 levels and corresponding reduction of calcitriol (the biologically active form of vitamin D). A series of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides have been synthesised using an efficient synthetic route and shown to be potent inhibitors of CYP24A1 (IC50 0.11–0.35?μM) compared with the standard ketoconazole. Molecular modelling using our CYP24A1 homology model showed the inhibitors to fill the hydrophobic binding site, forming key transition metal interaction between the imidazole nitrogen and the haem Fe3+ and multiple interactions with the active site amino acid residues.